Objective. Several autoimmune diseases have familial aggregation and, possibly, common genetic predispositions. In a large population-based study, we evaluated whether children born to mothers with systemic lupus erythematosus (SLE) have an increased risk of rheumatic and nonrheumatic autoimmune diseases versus children born to mothers without SLE.
Conclusion.
Although the vast majority of offspring have no autoimmune disease, children born to women with SLE may have an increased risk of nonrheumatic autoimmune diseases versus controls. Additional studies assessing offspring through to adulthood would be additionally enlightening.
Familial aggregation of autoimmune diseases suggests a common genetic predisposition and shared environmental factors. Concurrent cases of systemic lupus erythematosus (SLE) and other autoimmune diseases have been reported (1) , but, until recently, only a few small studies have evaluated the risk of autoimmune diseases in children born to mothers with SLE (2-4). The results were inconsistent, mainly because of small sample size. Robust data could be valuable when counseling families, and to prompt further study on the contributions of genetic, environmental, and in utero factors contributing to autoimmune disease susceptibility.
Therefore, using a large population-based study and specifically focusing on the childhood and adolescence periods, we aimed to determine whether children born to mothers with SLE have an increased risk of rheumatic and nonrheumatic autoimmune diseases compared to children born to mothers without SLE.
PATIENTS AND METHODS
Study cohort. We used the Offspring of SLE Mothers Registry (OSLER), a population-based cohort of 719 children born to mothers with SLE, matched to 8,493 control children in the province of Quebec, Canada. Using provincial administrative data for hospitalizations (Maintenance et exploitation des donn ees pour l' etude de la client ele hospitali ere; MED-ECHO) and physician billing (R egie de l'assurance maladie du Qu ebec; RAMQ), all women with SLE who had at least 1 hospitalization for a delivery (stillbirth or live birth), between January 1989 and December 2009, were identified. MED-ECHO has documented all hospitalizations in Quebec since 1987. All Quebec residents have public insurance covering hospitalizations and fee-for-service physician encounters; thus, the MED-ECHO and RAMQ physician billing databases hold information on essentially all births in the province. Exposure of interest. Based on a validated definition (5), using International Classification of Diseases, Ninth Revision (ICD-9), code 710.0 or ICD-10 code M32, women were identified as SLE cases if they had any of the following: 1) ≥1 hospitalization with a diagnosis of SLE (either primary or nonprimary) prior to the delivery, 2) a diagnosis of SLE (either primary or nonprimary) recorded at the time of their hospitalization for delivery, or 3) ≥2 physician visits with a diagnosis of SLE, occurring 2 months to 2 years apart, prior to the delivery. These women with SLE were individually matched at least 4:1 for age and year of delivery to women who did not have a diagnosis of SLE prior to or at the time of delivery.
Mother-child linkage was done using the mother's encrypted number, present in every child's file in the databases, and leading to very few linkage failures (<2%). In our current study, the exposed group consisted of children born to women with SLE, and the control group included children born to women without SLE.
Outcome assessment. The study interval spanned from birth to the first of the following: end of eligibility for RAMQ coverage (migration from Quebec), event of interest (rheumatic and nonrheumatic autoimmune diseases), age 18 years, death, or end of study (December 31, 2009).
Our ascertainment of autoimmune diseases in offspring was based on ≥1 hospitalization or ≥2 physician visits with a relevant ICD-9 and/or ICD-10 diagnostic code, at least 2 months apart but within 24 months. Relevant covariate assessment. Data on the demographics of the parents at the time of delivery, as well as infant birth weight and gestational age, were provided by the Institut de la statistique du Qu ebec. This information allowed determination of obstetric complications, such as small for gestational age babies (birth weight below the 10th percentile Canadian statistics for gestational age) (8) and premature births (babies born before 37 weeks' gestation).
By reviewing the MED-ECHO and RAMQ data, we identified comorbidities for all mothers, including hypertension, asthma, diabetes mellitus, and depression, based on ICD-9 and ICD-10 codes, with an indicated ≥1 hospitalization or ≥2 physician visits (at least 8 weeks apart) for the diagnosis of interest, as per previously validated methodology (9) . Most individuals of working age in Quebec have private insurance that covers prescription medications, and only those who are unemployed or on social assistance are covered under the public drug plan. This explains why we had information on medications for 22% of exposed children and 21% of controls, and not for the entire cohort. Indeed, relevant maternal medication exposures (i.e., antimalarials, glucocorticoids, and immunosuppressive drugs), based on at least 1 prescription filled during pregnancy, were obtained through the RAMQ prescription database, but only for those who benefited from the public drug plan throughout pregnancy.
Statistical analysis. We performed univariate and multivariate analyses using a generalized estimating equation method to estimate the odds ratio (OR) for the outcome of interest (i.e., autoimmune diseases), for children born to women with SLE, relative to the control group. We adjusted for maternal age, education, race/ethnicity, obstetric complications, calendar year of birth, and sex of the child. These analyses were performed using R software, version 2.15.1.
We also performed a sensitivity analysis further adjusting for cesarean section, as well as one further controlling for relevant maternal medications. Moreover, maternal history of nonrheumatic autoimmune diseases might be considered an intermediate variable in the causal pathway between the exposure (maternal SLE) and the outcome (autoimmune diseases) in the offspring. Although one should not adjust for an intermediate variable to estimate the total effect (i.e., direct and indirect effect) of an exposure on the outcome, we sought to assess the direct effect of maternal SLE (independent of maternal nonrheumatic autoimmune diseases) by performing a sensitivity analysis further controlling for maternal nonrheumatic autoimmune diseases (using the same case definition as in offspring). The study was approved by the Commission d'acc es a l'information du Qu ebec and the McGill University Research Ethics Board. Informed consent is not required for administrative database research in Quebec.
RESULTS
A total of 509 women with SLE had 719 children, while 5,824 matched controls had 8,493 children. The mean AE SD maternal SLE disease duration was 3.7 AE 4.0 years, and mean AE SD follow-up of children was 9.1 AE 5.8 years. Mothers with SLE had similar demographic characteristics in comparison to control mothers, with the exception that the former were less likely to be white, had more comorbidities, and experienced substantially more obstetric complications, such as preterm births and cesarean sections (Table 1 ). Compared to children of the controls, SLE offspring were more exposed in utero to drugs, particularly glucocorticoids and antimalarials.
In comparison to controls, children born to mothers with SLE had similar records of rheumatic diagnoses . In both groups, the most frequently observed nonrheumatic autoimmune diseases were Crohn's disease (0.56% of SLE offspring and 0.19% of control children) and type 1 diabetes mellitus (0.42% of SLE offspring and 0.22% of control children) ( Table 2) .
In multivariate analysis (n = 9,212), the adjusted SLE effect estimate was inconclusive for rheumatic autoimmune diseases (OR 0.71 [95% CI 0.11-4.82]). However, SLE offspring had a substantially increased risk of nonrheumatic autoimmune diseases compared to control children (OR 2.30 [95% CI 1.06-5.03]) ( Table 3 ). In the analysis further controlling for cesarean section (n = 9,212), the adjusted SLE effect estimate remained similar for nonrheumatic autoimmune diseases (OR 2.27 [95% CI 1.02-5.06]). In the subsample of children born to mothers with public drug coverage (155 SLE offspring and 1,770 control offspring), we identified only 1 case of rheumatic autoimmune disease in 1 control child, and 7 cases of nonrheumatic autoimmune diseases in 2 SLE offspring and 5 control children. None of these 8 offspring were exposed in utero to any drugs of interest (antimalarials, glucocorticoids, immunosuppressive drugs, antidepressants, or anticonvulsants). When we repeated the multivariate analysis further controlling for maternal history of nonrheumatic autoimmune diseases, we found that the independent effect of maternal SLE on the risk of nonrheumatic autoimmune diseases in offspring was almost identical to the one obtained from the primary analysis (OR 2.33 [95% CI 1.04-5.19]).
DISCUSSION
Within a large cohort of SLE offspring, although we observed a trend toward more nonrheumatic diseases in SLE offspring during the childhood and adolescence periods relative to children from the general population, the absolute numbers were small. The effect of maternal SLE on the risk of nonrheumatic autoimmune diseases was not completely explained by variables such as preterm birth and cesarean section, which have been associated with an increased risk of certain autoimmune diseases in offspring, such as type 1 diabetes mellitus (10, 11) .
Previous studies evaluating the risk of autoimmune diseases in children born to mothers with SLE showed 11 (7.1)* 0 (0.0) † Antidepressants 11 (7.1)* 52 (2.9) † Anticonvulsants 1 (0.6)* 7 (0.4) † * Denominator used for proportion is number of children born to systemic lupus erythematosus (SLE) mothers with public drug coverage during pregnancy. † Denominator used for proportion is number of children born to control mothers with public drug coverage during pregnancy.
inconsistent results. One population-based family study assessed risk of SLE in subjects with affected first-degree relatives (12) . The authors estimated the SLE prevalence ratios between first-degree relatives of an individual with SLE and the Taiwan population. A 14-fold increased risk of SLE in subjects with affected mothers was found compared to the general population. However, timing of SLE diagnosis in both mother and offspring was not considered. The risk of developing SLE during childhood was not specifically evaluated.
McAllister et al assessed the parent-reported prevalence of immune disorders in 154 children born to mothers with SLE compared to 154 unexposed children. They found that children in the SLE group had significantly more reports of inflammatory bowel disease and thyroid disease (2) . Furthermore, after administering questionnaires to mothers with anti-Ro and/or anti-La antibodies (with or without SLE) of 49 children age ≥8 years (mean age 15 years), Martin et al reported an increased risk of JIA and nonrheumatic autoimmune diseases (such as Hashimoto thyroiditis, psoriasis, iritis, and diabetes mellitus) in children who developed neonatal lupus compared to their unaffected siblings (4). Sanchez-Manubens et al conducted telephone surveys on a cohort of 39 children born to 29 mothers with autoimmune diseases (65% of whom had SLE), with a mean follow-up of children of 4 years (range 1-7 years) (3). They reported the case of 1 boy born to a mother with SLE who developed oligoarticular JIA with positive antinuclear antibody. There were no cases of thyroid disease, celiac disease, diabetes mellitus, or other autoimmune diseases. The inconsistent conclusions of these observational studies could be the result of their small sample size or could be due to potential imperfect ascertainment.
Our study has many strengths. We had a large sample size, which provided enough power to assess rare events such as autoimmune diseases. In addition, the population-based nature of our study sample reduces the possibility for selection bias. Moreover, Quebec's administrative databases are a valid data source for observational studies of SLE subjects, with prior work from our group showing that our SLE case definition has a very high specificity (0.999) (5) . Prior studies have shown good validity for type 1 diabetes mellitus and inflammatory bowel disease case definition (6,7), as well as for the pregnancy-related variables (9) .
We need to acknowledge potential limitations to our study as well. First, in administrative databases, there are inherent sources of uncertainty about case ascertainment. To minimize this, we used case definitions that have shown good validity in prior studies (6, 7) . Furthermore, we had information on in utero drug exposures only in the subsample of children with maternal drug coverage throughout pregnancy, representing~20% of the entire cohort. This reduced the power of our subsample analysis investigating the effect of in utero drug exposures on the risk of autoimmune diseases. We were unable to detect an increased risk of rheumatic autoimmune diseases in SLE offspring, as the CI was large and included the null value. In the general population, observational studies have shown that rheumatic autoimmune diseases are rarer during childhood. For instance, compared to the prevalence of 20-150 cases per 100,000 adults in adult-onset SLE, the prevalence of pediatric-onset SLE has been estimated to be 3.3-8.8 per 100,000 children (13) . Follow-up of OSLER offspring, into adulthood, would be additionally helpful.
It should be noted that the occurrence of autoimmune diseases in children born to women with SLE is uncommon, and the vast majority of offspring do not have any autoimmune disease, as far as we have been able to study them. There is increasing evidence that there is cross-talk between a pregnant woman and the fetus. Studies indicate that maternal antibodies, immune complexes, inflammatory mediators, and maternal cells are transferred in utero and program the fetal immune system (14) . Maternal autoimmune disorders, such as SLE, might modify these signals and may thereby alter immunity in early life and childhood. A better understanding of the maternal programming of the fetal immune system could potentially help explain the increased risk of nonrheumatic autoimmune diseases in SLE offspring.
In conclusion, compared to children from the general population, children born to women with SLE might have an increased risk of nonrheumatic autoimmune diseases during the childhood and adolescence periods. The effect estimate was inconclusive for the risk of rheumatic autoimmune disease. Future studies throughout adulthood might show increased risk at a later age. These data could be considered when counseling families with affected mothers. Further research is warranted to investigate the relative contribution of genetic factors and shared environmental exposures, as well as in utero exposure to inflammation and maternal autoantibodies.
